This trial looks at how well two targeted treatments work for patients with certain types of salivary gland cancer. The study compares ado-trastuzumab emtansine to standard treatment, which includes chemotherapy with docetaxel and trastuzumab. It also tests trastuzumab deruxtecan for patients with lower levels of HER2 in their cancer. The goal is to see which treatment helps patients live longer without their cancer getting worse and how well these treatments work overall.
The trial's ID number is NCT05408845. It is a Phase 2 trial, which means it is looking at how well the treatments work and how safe they are. The trial is regulated by the FDA and aims to include about 146 participants.
Who can join
Adults 18 and older can join the trial. It is for men and women with specific types of recurrent or metastatic salivary gland cancer that is either HER2-positive or HER2-low expressing. Those with brain metastases may join if their condition is stable. The trial team will check to confirm eligibility.
Conditions
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be placed into one of three groups by chance. One group will receive docetaxel and trastuzumab, another group will receive ado-trastuzumab emtansine, and the third group will receive trastuzumab deruxtecan. Everyone will receive treatment every three weeks for up to six cycles, depending on their health and how well the treatment works. Patients will also have imaging tests and may need to give blood or tissue samples.
Where
This trial is enrolling at 152 locations. Recruiting sites are listed first.
Abbott-Northwestern Hospital
Minneapolis, Minnesota
Recruiting
Arnold Palmer Cancer Center Medical Oncology Norwin